– UK, Brentford – GlaxoSmithKline Plc (LON: GSK | NYSE: GSK) today announced that Charlie Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
“I am delighted Charlie is joining the GSK Board and has agreed to succeed Judy in 2021 as Chair of our Audit & Risk Committee. He brings a wealth of financial and management experience in global biopharma which will be invaluable to the Board in the coming years as it oversees the delivery of GSK’s strategy, including the separation of the Group and the creation of two outstanding new companies,” said Sir Jonathan Symonds, Chairman.
On joining the Board Charlie will become a member of the Audit & Risk Committee. He will succeed Judy Lewent as Chair of this Committee following approval of 2020 Annual Report.
About Charlie Bancroft
Charlie has recently retired from a successful career at Bristol Myers Squibb where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held positions of increasing responsibility within the finance organisation and had commercial operational responsibility for Latin America, Middle East, Africa, Canada, Japan and several Pacific Rim countries. He was appointed CFO in 2010, CFO and EVP, Global Business Operations in 2016 and EVP and Head of Integration and Strategy & Business Development in 2019. Charlie successfully steered BMS through a period of strategic transformation, including the recent $74bn acquisition of Celgene.
Charlie served as a member of the Board of Colgate-Palmolive Company from 2017 until March 2020.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
For more information: https://www.gsk.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.